Relationship of AgNOR counts and nuclear DNA content to survival in patients with parathyroid carcinoma

Endocrine-Related Cancer

Volumn 11, Issue 3, 2004, Pages 563-569

  Lumachi, F ^a   Ermani, M ^a   Marino, F ^a   Poletti, A ^a   Basso, S M M ^a   Iacobone, M ^a   Favia, G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; DNA; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHROMOSOME NOR; CLINICAL ARTICLE; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; SILVER STAINING;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; ANEUPLOIDY; CELL NUCLEUS; CELL PROLIFERATION; DIPLOIDY; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; NUCLEOLUS ORGANIZER REGION; PARATHYROID NEOPLASMS; PROGNOSIS; SILVER STAINING; SURVIVAL RATE;

EID: 4944253919     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00792     Document Type: Article

References (25)

1. Abbona GC, Papotti M, Gasparri G & Bussolati G 1995 Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Human Pathology 26 135-138.
2. Arnaud CD 1994 The calciotropic hormones & metabolic bone disease. In Basic and Clinical Endocrinology, pp 227-306. Eds FS Greespan & JD Baxter. East Norwalk: Appleton & Lange.
3. August DA, Flynn SD, Jones MA, Bagwell CB & Kinder BK 1993 Parathyroid carcinoma: the relationship of nuclear DNA content to clinical outcome. Surgery 113 290-296.
4. Bocsi J, Perner F, Szucs J, Glaz E & Kopper L 1998 DNA content of parathyroid tumors. Anticancer Research 18 2901-2904.
5. Bondeson L, Sandelin K & Grimelius L 1993 Histopathological variables and DNA cytometry in parathyroid carcinoma. American Journal of Surgical Pathology 17 820-829.
6. Clayman GL, Gonzales HE, El-Nagger A & Vassilopoulos-Sellin R 2004 Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 109 900-905.
7. Croker J & Nar P 1987 Nucleolar organizer regions in lymphomas. Journal of Pathology 151 111-118.
8. Favia G, Lumachi F, Polistina F & D'Amico DF 1998 Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World Journal of Surgery 22 1225-1230.
9. Hundhal SA, Fleming ID, Fremgen AM & Menck HR 1999 Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995. Cancer 86 538-544.
10. Kameyama K & Takami H 1999 DNA cytofluorimetric analysis using HP/DAPI double staining of parathyroid carcinoma arising in a patient with chronic renal failure and secondary hyperparathyroidism. Oncology Reports 6 1345-1347.
11. Kameyama K, Takami H, Umemura S, Osamura YR, Wada N, Sugino K, Mimura T & Ito K 2000 PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Annals of Surgical Oncology 7 301-305.
12. Kanematsu E, Matsui H, Deguchi T, Yamamoto O, Korematsu M, Kobayashi A, Nezasa SI, Yamamoto N, Takeuchi T, Tanaka T & Kawada Y 1997 Significance of AgNOR counts for distinguishing carcinoma from adenoma and hyperplasia in parathyroid gland. Human Pathology 28 421-427.
13. Kebebew E, Arici C, Duh QY & Clark OH 2001 Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Archives of Surgery 136 878-885.
14. Levin K, Galante M & Clark 1987 Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 101 647-660.
15. Lumachi F, Zucchetta P, Marzola MC, Boccagni P, Angelini F, Bui F, D'Amico DF & Favia G 2000 Advantages of combined technetium-99m-sestamibi scintigraphy and high-resolution ultrasonography in parathyroid localization: comparative study in 91 patients with primary hyperparathyroidism. European Journal of Endocrinology 143 755-760.
16. Lumachi F, Ermani M, Basso S, Zucchetta P, Borsato N & Favia G 2001 Localization of parathyroid tumours in the minimally invasive era: which technique should be chosen? Population based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid glands detection. Endocrine-Related Cancer 8 63-69.
17. Mallette LE 1992 DNA quantitation in the study of parathyroid lesions. A review. American Journal of Clinical Pathology 98 305-311.
18. Obara T, Fujimoto Y, Hirayama A, Okamoto T, Hirayama A, Ito Y, Kodama T & Ogata T 1990 Flow cytometry DNA analysis of parathyroid tumors with special reference to its diagnostic and prognostic value in parathyroid carcinoma. Cancer 65 1789-1793.
19. Obara T, Okamoto T, Kanbe M & Iihara M 1997 Functioning parathyroid carcinoma: clinicopathological features and rational treatment. Seminars of Surgical Oncology 13 134-141.
20. Ploton D, Menager M, Jeanneson P, Himber G, Pigeon F & Adnet JJ 1986 Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochemical Journal 18 5-14.
21. Shane E 2001 Parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 485-493.
22. Shantz A & Castleman B 1973 Parathyroid carcinoma: a study of 70 cases. Cancer 31 600-605.
23. Shoback D, Marcus R, Bikle D & Strewler GJ 2001 Mineral metabolism & metabolic bone disease. In Basic and Clinical Endocrinology, pp 485-493. Eds FS Greenspan & DG Gardner. New York: McGraw-Hill.
24. Trerè D, Farabegoli F, Cancelliere A, Ceccarelli C, Eusebi V & Derenzini M 1991 AgNOR area in interphase nucleoli of human tumours correlates with the proliferative activity evaluated by bromodeoxyuridine labeling and Ki-67 immunostaining. Journal of Pathology 165 53-59.
25. Tuccari G, Abbona GC, Giuffrè G, Papotti M, Gasparri G, Barresi G & Bussolati G 2000 AgNOR quantity as a prognostic tool in hyperplastic and neoplastic parathyroid glands. Virchows Archive 437 298-303.